Takeda enters $790m cancer development deal
pharmafile | October 11, 2016 | News story | Manufacturing and Production, Research and Development | Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody
Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s Humabody platform as a base for indications with high unmet need.
According the Crescendo, Humabodies are a “new class of extremely small, robust and potent protein therapeutics” based on fully human VH domain building blocks which enable the rapid assembly and screening of a range of bi- and multi-specific candidates. The partnerships hopes to use this transgenic platform to optimally configure Humabody candidates against multiple targets nominated by Takeda.
The deal breaks down into a $36 million upfront payment from Takeda to Crescendo accounting for investment and various milestones and up to $754 million payments and royalties.
“This collaboration with Takeda represents a significant step forward for Crescendo. It provides validation of our transgenic platform and our capabilities to rapidly assemble and configure small, differentiated Humabody-based therapeutics, opening routes to novel biology,” said Dr Peter Pack, CEO at Crescendo Biologics. “As a leading global pharmaceutical company, Takeda brings extraordinary expertise in the oncology area with significant capabilities in developing and delivering novel medicines to patients. This first major collaboration enables us to potentially broaden and accelerate innovative Humabody-based product candidates.”
Takeda chief medical and scientific officer Andrew Plump added: “We see significant potential in Crescendo and its innovative technology to develop unique, small and customisable Humabody-based therapeutics. Working together with Crescendo will enable us to leverage its important technology to support Takeda’s goal of developing next generation, highly modular and targeted therapies to treat cancer.”
Matt Fellows
Related Content
Von Willebrand disease – increasing awareness and access to vital care
Pharmafile talks to Anthea Cherednichenko, Vice President Franchise Head Haematology and Transplant at Takeda about …
Combination treatments: Takeda’s Implementation Framework and the broader landscape
Pharmafile talks to Emma Roffe, Oncology Country Head (UK & Ireland) about the combination treatment …
Central nervous system cancer metastases – the evolution of diagnostics and treatment
The current forms of immunotherapy, how T cell therapy works and what the future holds
